Literature DB >> 18617599

Health-related quality of life of long-term high-grade glioma survivors.

Ingeborg Bosma1, Jaap C Reijneveld, Linda Douw, Maaike J Vos, Tjeerd J Postma, Neil K Aaronson, Martin Muller, W Peter Vandertop, Ben J Slotman, Martin J B Taphoorn, Jan J Heimans, Martin Klein.   

Abstract

The objective of this study was to compare the health-related quality of life (HRQOL) of long-term to short-term high-grade glioma (HGG) survivors, determine the prognostic value of HRQOL for overall survival, and determine the effect of tumor recurrence on HRQOL for long-term survivors. Following baseline assessment (after surgery, before radiotherapy), self-perceived HRQOL (using the Medical Outcomes Study Short Form 36 [SF-36]) and brain tumor-specific symptoms (using the 20-item Brain Cancer Module) were assessed every 4 months until 16 months after histological diagnosis. Kaplan-Meier survival analysis and the Cox proportional hazards model were performed to estimate overall survival of patients with impaired scores on the aggregated SF-36 higher-order summary scores measuring physical functioning on a physical component scale and on a mental component scale (MCS). Sixteen patients with a short-term survival (baseline and 4-month follow-up) and 16 with a long-term survival (follow-up until 16 months after diagnosis) were selected out of 68 initially recruited HGG patients. At baseline, the short-term and long-term survivors did not differ in their HRQOL. Between baseline and the 4-month follow-up, HRQOL of short-term survivors deteriorated, whereas the long-term survivors improved to a level comparable to healthy controls. Patients with impaired mental functioning (MCS) at baseline had a shorter median survival than patients with normal functioning. After accounting for differences in patient and tumor characteristics, however, mental functioning was not independently related to poorer overall survival. Not surprisingly, in the group of long-term survivors, the five patients with recurrence had a more compromised HRQOL at the 16-month follow-up compared to the 11 patients without recurrence. We concluded that baseline HRQOL is not related to duration of survival and that long-term survivors show improvement of HRQOL to a level comparable to that of the healthy.

Entities:  

Mesh:

Year:  2008        PMID: 18617599      PMCID: PMC2718959          DOI: 10.1215/15228517-2008-049

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  18 in total

1.  Cognitive function as a predictor of survival in patients with recurrent malignant glioma.

Authors:  C A Meyers; K R Hess; W K Yung; V A Levin
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Quality of life (QoL) as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy.

Authors:  S Sehlen; M Lenk; H Hollenhorst; B Schymura; U Aydemir; P Herschbach; E Dühmke
Journal:  Onkologie       Date:  2003-02

Review 4.  Quality-of-life issues in patients with malignant gliomas.

Authors:  R D Aiken
Journal:  Semin Oncol       Date:  1994-04       Impact factor: 4.929

5.  Does brain tumor histology influence cognitive function?

Authors:  Anne E Kayl; Christina A Meyers
Journal:  Neuro Oncol       Date:  2003-10       Impact factor: 12.300

6.  The trends in incidence of primary brain tumors in the population of Rochester, Minnesota.

Authors:  K Radhakrishnan; B Mokri; J E Parisi; W M O'Fallon; J Sunku; L T Kurland
Journal:  Ann Neurol       Date:  1995-01       Impact factor: 10.422

7.  The prognostic value of cognitive functioning in the survival of patients with high-grade glioma.

Authors:  M Klein; T J Postma; M J B Taphoorn; N K Aaronson; W P Vandertop; M Muller; H M van der Ploeg; J J Heimans
Journal:  Neurology       Date:  2003-12-23       Impact factor: 9.910

Review 8.  Toward a theoretical model of quality-of-life appraisal: Implications of findings from studies of response shift.

Authors:  Bruce D Rapkin; Carolyn E Schwartz
Journal:  Health Qual Life Outcomes       Date:  2004-03-15       Impact factor: 3.186

9.  Reconsidering the psychometrics of quality of life assessment in light of response shift and appraisal.

Authors:  Carolyn E Schwartz; Bruce D Rapkin
Journal:  Health Qual Life Outcomes       Date:  2004-03-23       Impact factor: 3.186

10.  The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study.

Authors:  M Mauer; R Stupp; M J B Taphoorn; C Coens; D Osoba; C Marosi; R Wong; O de Witte; J G Cairncross; F Efficace; R O Mirimanoff; P Forsyth; M J van den Bent; M Weller; A Bottomley
Journal:  Br J Cancer       Date:  2007-07-03       Impact factor: 7.640

View more
  26 in total

1.  Health-related quality of life in high-grade glioma patients: a prospective single-center study.

Authors:  Cagdas Yavas; Faruk Zorlu; Gokhan Ozyigit; Murat Gurkaynak; Guler Yavas; Deniz Yuce; Mustafa Cengiz; Ferah Yildiz; Fadil Akyol
Journal:  Support Care Cancer       Date:  2011-12-13       Impact factor: 3.603

Review 2.  Review on quality of life issues in patients with primary brain tumors.

Authors:  Martin J B Taphoorn; Eefje M Sizoo; Andrew Bottomley
Journal:  Oncologist       Date:  2010-05-27

Review 3.  Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.

Authors:  Dina Randazzo; Katherine B Peters
Journal:  CNS Oncol       Date:  2016-07-11

Review 4.  Quality of life research in neuro-oncology: a quantitative comparison.

Authors:  Elizabeth Klein; David Altshuler; Abhirami Hallock; Nicholas Szerlip
Journal:  J Neurooncol       Date:  2013-11-05       Impact factor: 4.130

5.  The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.

Authors:  Przemyslaw Wielgat; Robert Czarnomysy; Emil Trofimiuk; Halina Car
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

Review 6.  Living longer with adult high-grade glioma: setting a research agenda for patients and their caregivers.

Authors:  Bethany Russell; Anna Collins; Michael Dally; Anthony Dowling; Michelle Gold; Michael Murphy; Jennifer Philip
Journal:  J Neurooncol       Date:  2014-07-01       Impact factor: 4.130

7.  Factors influencing quality of life in patients with benign primary brain tumors: prior to and following surgery.

Authors:  Shiow-Luan Tsay; Jui-Yen Chang; Patsy Yates; Kuan-Chia Lin; Shu-Yuan Liang
Journal:  Support Care Cancer       Date:  2010-11-24       Impact factor: 3.603

8.  Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.

Authors:  Esther J J Habets; Linda Dirven; Ruud G Wiggenraad; Antoinette Verbeek-de Kanter; Geert J Lycklama À Nijeholt; Hanneke Zwinkels; Martin Klein; Martin J B Taphoorn
Journal:  Neuro Oncol       Date:  2015-09-18       Impact factor: 12.300

9.  Cognitive strategies and quality of life of patients with high-grade glioma.

Authors:  C Lucchiari; A Botturi; A Silvani; E Lamperti; P Gaviani; A Innocenti; C Y Finocchiaro; M Masiero; G Pravettoni
Journal:  Support Care Cancer       Date:  2015-03-12       Impact factor: 3.603

10.  Neurocognitive training in patients with high-grade glioma: a pilot study.

Authors:  Marco Ronald Hassler; Katarzyna Elandt; Matthias Preusser; Johann Lehrner; Petra Binder; Karin Dieckmann; Andrea Rottenfusser; Christine Marosi
Journal:  J Neurooncol       Date:  2009-09-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.